These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34089886)

  • 1. Inverse association between hypertension treatment and COVID-19 prevalence in Japan.
    Kinoshita M; Sato K; Vellingiri B; Green SJ; Tanaka M
    Int J Infect Dis; 2021 Jul; 108():517-521. PubMed ID: 34089886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
    Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
    Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in Patients with Hypertension.
    Quinaglia T; Shabani M; Rezaei N
    Adv Exp Med Biol; 2021; 1318():243-261. PubMed ID: 33973183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
    Edmonston DL; South AM; Sparks MA; Cohen JB
    Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.
    Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K
    Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
    Vázquez-Cornejo E
    Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.
    Kow CS; Hasan SS
    Expert Rev Cardiovasc Ther; 2021 Jan; 19(1):99-100. PubMed ID: 33112190
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19.
    Rieder M; Wirth L; Pollmeier L; Jeserich M; Goller I; Baldus N; Schmid B; Busch HJ; Hofmann M; Kern W; Bode C; Duerschmied D; Lother A
    Am J Hypertens; 2021 Apr; 34(3):278-281. PubMed ID: 33043967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19.
    Rouette J; Suissa K; Azoulay L
    Epidemiology; 2020 Nov; 31(6):e52-e53. PubMed ID: 33555810
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
    Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
    PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
    Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
    BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
    Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to the letter to the editor entitled 'Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic'.
    Bottino LG; Fuchs FD
    Expert Rev Cardiovasc Ther; 2021 Feb; 19(2):189-190. PubMed ID: 33297777
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity.
    Ruocco G; Feola M; Palazzuoli A
    Int J Infect Dis; 2020 Jun; 95():373-375. PubMed ID: 32335337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells.
    Pires de Souza GA; Osman IO; Le Bideau M; Baudoin JP; Jaafar R; Devaux C; La Scola B
    Front Cell Infect Microbiol; 2021; 11():639177. PubMed ID: 34178717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension.
    Feng B; Zhang D; Wang Q; Yu F; Zou Q; Xie G; Wang R; Yang X; Chen W; Lou B; Zheng S; Chen Y
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):330-340. PubMed ID: 33835767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.
    Iaccarino G; Grassi G; Borghi C; Ferri C; Salvetti M; Volpe M;
    Hypertension; 2020 Aug; 76(2):366-372. PubMed ID: 32564693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
    Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
    J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study).
    Mustafic H; Fayssoil A; Josseran L; Ouadahi M; Grimaldi-Bensouda L; Dubourg O; Annane D; Mansencal N
    Am J Cardiol; 2021 May; 147():58-60. PubMed ID: 33617818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
    Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
    Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.